GlassScriptPhysician profile
Dawn M Arnold
NPI 1447366588
$4,296.89
in general payments reported to CMS, 2019-2025
23 companies · $693 in 2025
The $693 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $230 · 2021: $293 · 2022: $395 · 2023: $525 · 2024: $1,955 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Debt Forgiveness: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.57 |
| Debt Forgiveness | $818.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $818.65 | 2024 | |
| Bausch & Lomb Americas INC. | $471.42 | 2023-2025 | Miebo, Infuse, Xiidra |
| Allergan, INC. | $406.84 | 2020-2022 | |
| Alcon Vision LLC | $343.58 | 2021-2025 | Dailies Total1, Total30, Precision 1 |
| Glaukos Corporation | $328.16 | 2024 | Ce-Marked Kxla System |
| Sight Sciences, INC. | $237.24 | 2019-2021 | |
| Abbvie INC. | $232.36 | 2023-2025 | Durysta |
| Coopervision INC. | $189.34 | 2021-2025 | Myday Contact Lens, Misight Contact Lens |
| Dompe US, INC. | $161.11 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $147.24 | 2024-2025 | Xdemvy |
| Lkc Technologies, INC. | $142.55 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $105.89 | 2024 | |
| Mallinckrodt Hospital Products INC. | $105.87 | 2025 | Acthar |
| Genzyme Corporation | $102.77 | 2024 | |
| Abb Con-Cise Optical Group LLC | $97.35 | 2023-2025 | Contact Lens, Spectacle Lenses |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $95.43 | 2020 | |
| Visioneering Technologies, INC. | $92.89 | 2019 | |
| Biotissue Holdings INC. | $76.83 | 2024 | |
| Samsara Vision | $50.00 | 2022 | |
| Kala Pharmaceuticals, INC. | $42.97 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $15.40 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.